Who is sponsoring NCT03896152?

NCT03896152 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03896152?

Interventions in NCT03896152: LNP023.

What condition does NCT03896152 study?

NCT03896152 studies Paroxysmal Nocturnal Hemoglobinuria.

Is NCT03896152 still recruiting?

NCT03896152 is currently completed. Last updated 18 June 2024.

Are results published for NCT03896152?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-06-18 · How we verify

NCT03896152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed Phase 2 Results posted Last updated 18 June 2024

What this trial tests

Phase 2 trial testing LNP023 in Paroxysmal Nocturnal Hemoglobinuria in 13 participants. Completed in 9 February 2022.

Timeline

5 April 2019

Primary endpoint
7 April 2020

9 February 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	5 April 2019
Primary completion	7 April 2020
Estimated completion	9 February 2022
Sites	5 locations across Taiwan, Singapore, Malaysia, South Korea

Drugs / interventions tested

LNP023 — full drug profile →

Conditions studied

Paroxysmal Nocturnal Hemoglobinuria — all drugs for Paroxysmal Nocturnal Hemoglobinuria →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Paroxysmal Nocturnal Hemoglobinuria. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Summary of Lactate Dehydrogenase (LDH) Responders Primary · Week 2, week 4, week 8 and week 12

A responder was defined as a patient with at least 60% reduction in LDH compared to Baseline or LDH below the upper limit of normal at any time up to and including Week 12 for that patient.

Responders at week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	6
LNP023 50 mg Bid/200 mg Bid	5

Responders at week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	7
LNP023 50 mg Bid/200 mg Bid	5

Responders at week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	7
LNP023 50 mg Bid/200 mg Bid	5

Responders at week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	7
LNP023 50 mg Bid/200 mg Bid	5

Percent Change From Baseline in LDH Levels Secondary · Baseline, week 2, week 4, week 8 and week 12

LDH was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of Paroxysmal nocturnal hemoglobinuria (PNH)-associated hemolysis. Active hemolysis is defined by an LDH value ≥ 1.5x upper limit of normal (ULN) Baseline LDH was calculated as the average of the last three screening values prior to randomization. Serum was used to calculate the LDH values

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-76.52	± 18.478
LNP023 50 mg Bid/200 mg Bid	-84.98	± 8.186

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-79.75	± 16.025
LNP023 50 mg Bid/200 mg Bid	-89.72	± 5.430

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-81.73	± 22.832
LNP023 50 mg Bid/200 mg Bid	-88.30	± 8.744

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-86.17	± 8.896
LNP023 50 mg Bid/200 mg Bid	-85.92	± 9.013

Change From Baseline in Hemoglobin Secondary · Baseline, Week 2, week 4, week 8 and week 12

Hemoglobin was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of PNH-associated hemolysis. Whole blood was used to calculate the hemoglobin values.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	6.88	± 5.812
LNP023 50 mg Bid/200 mg Bid	31.83	± 10.362

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	9.61	± 11.857
LNP023 50 mg Bid/200 mg Bid	36.58	± 17.875

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	15.02	± 9.154
LNP023 50 mg Bid/200 mg Bid	38.08	± 25.956

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	23.36	± 14.378
LNP023 50 mg Bid/200 mg Bid	37.11	± 26.171

Change From Baseline in Free Hemoglobin Secondary · Baseline, Week 2, week 4, week 8 and week 12

Free hemoglobin was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of PNH-associated hemolysis. Whole blood was used to calculate the hemoglobin values.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-39.84	± 26.521
LNP023 50 mg Bid/200 mg Bid	-13.53	± 5.093

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-31.88	± 35.314
LNP023 50 mg Bid/200 mg Bid	-29.26	± 24.218

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-31.85	± 27.517
LNP023 50 mg Bid/200 mg Bid	-16.31	± 48.877

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-39.58	± 31.612
LNP023 50 mg Bid/200 mg Bid	-14.75	± 6.293

Change From Baseline in Carboxyhemoglobin Secondary · Baseline, Week 2, week 4, week 8 and week 12

Carboxyhemoglobin was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Whole blood was used to calculate the carboxyhemoglobin values.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-0.01	± 0.516
LNP023 50 mg Bid/200 mg Bid	-0.72	± 0.697

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-0.36	± 0.472
LNP023 50 mg Bid/200 mg Bid	-0.98	± 0.582

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-0.50	± 0.664
LNP023 50 mg Bid/200 mg Bid	-1.12	± 0.916

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-0.95	± 0.316
LNP023 50 mg Bid/200 mg Bid	-0.78	± 1.704

Change From Baseline in Absolute Reticulocyte Count (ARC) Secondary · Baseline, week 2, week 4, week 8 and week 12

Reticulocyte count was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Whole blood was used to calculate the absolute reticulocyte count.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-83.00	± 78.750
LNP023 50 mg Bid/200 mg Bid	-94.23	± 112.649

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-118.44	± 76.736
LNP023 50 mg Bid/200 mg Bid	-132.63	± 91.109

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-113.71	± 72.300
LNP023 50 mg Bid/200 mg Bid	-119.43	± 117.048

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-93.00	± 93.425
LNP023 50 mg Bid/200 mg Bid	-84.92	± 123.408

Red Blood Cell Count: Change From Baseline in Erythrocytes Secondary · Baseline, week 2, week 4, week 8 and week 12

Erythrocytes were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Whole blood was used to calculate erythrocytes values.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.49	± 0.194
LNP023 50 mg Bid/200 mg Bid	1.02	± 0.407

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.74	± 0.401
LNP023 50 mg Bid/200 mg Bid	1.26	± 0.619

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	1.16	± 0.396
LNP023 50 mg Bid/200 mg Bid	1.38	± 0.796

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	1.38	± 0.531
LNP023 50 mg Bid/200 mg Bid	1.38	± 0.770

Change From Baseline in C3 Fragment Deposition on PNH RBC Secondary · Baseline, week 2, week 4, week 8 and week 12

C3 fragment deposition on paroxysmal nocturnal hemoglobinuria red blood cell (PNH RBC) was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Accumulation of C3 fragments on red blood cells make them prone to phagocytosis causing extravascular hemolysis. Whole blood was used to calculate C3 fragment deposition on PNH RBC values.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-1.31	± 0.932
LNP023 50 mg Bid/200 mg Bid	-1.88	± 1.457

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-1.43	± 1.217
LNP023 50 mg Bid/200 mg Bid	-2.74	± 2.584

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-1.85	± 1.293
LNP023 50 mg Bid/200 mg Bid	-2.90	± 2.654

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-1.65	± 1.221
LNP023 50 mg Bid/200 mg Bid	-2.75	± 3.002

Mean Haptoglobin Levels Secondary · Baseline, week 2, week 4, week 8 and week 12

Haptoglobin levels were used as a hemolysis marker to determine the effect of iptacopan on the reduction of PNH-associated hemolysis. Serum was used to calculate haptoglobin levels.

Baseline

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.05	± 0.000
LNP023 50 mg Bid/200 mg Bid	0.05	± 0.000

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.27	± 0.251
LNP023 50 mg Bid/200 mg Bid	0.41	± 0.499

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.24	± 0.255
LNP023 50 mg Bid/200 mg Bid	0.49	± 0.490

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.38	± 0.456
LNP023 50 mg Bid/200 mg Bid	0.41	± 0.374

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	0.25	± 0.356
LNP023 50 mg Bid/200 mg Bid	0.18	± 0.225

Change From Baseline in Total Bilirubin Secondary · Baseline, week 2, week 4, week 8 and week 12

Bilirubin levels were used as a hemolysis marker to determine the effect of iptacopan on the reduction of PNH-associated hemolysis. Serum was used to calculate bilirubin levels.

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-19.81	± 7.855
LNP023 50 mg Bid/200 mg Bid	-23.93	± 16.735

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-19.95	± 10.620
LNP023 50 mg Bid/200 mg Bid	-25.93	± 15.992

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-20.24	± 12.612
LNP023 50 mg Bid/200 mg Bid	-25.53	± 16.471

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	-21.61	± 5.998
LNP023 50 mg Bid/200 mg Bid	-23.17	± 18.195

Mean Platelets Count Secondary · Baseline, week 2, week 4, week 8 and week 12

Platelet counts were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Whole blood was used to calculate platelets count.

Baseline

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	190.45	± 59.938
LNP023 50 mg Bid/200 mg Bid	156.42	± 52.321

Week 2

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	223.71	± 76.707
LNP023 50 mg Bid/200 mg Bid	158.20	± 62.683

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	203.17	± 68.520
LNP023 50 mg Bid/200 mg Bid	138.20	± 57.085

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	184.43	± 50.856
LNP023 50 mg Bid/200 mg Bid	141.20	± 46.569

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	189.33	± 54.617
LNP023 50 mg Bid/200 mg Bid	140.75	± 59.618

Mean Ferritin Levels Secondary · Baseline, Week 4, Week 8 and week 12

Ferritin levels were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Serum was used to calculate ferritin levels.

Baseline

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	176.97	± 404.254
LNP023 50 mg Bid/200 mg Bid	258.90	± 418.114

Week 4

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	174.21	± 431.042
LNP023 50 mg Bid/200 mg Bid	287.88	± 517.901

Week 8

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	178.31	± 443.346
LNP023 50 mg Bid/200 mg Bid	304.74	± 521.535

Week 12

Group	Value	95% CI
LNP023 25 mg Bid/100 mg Bid	203.22	± 454.296
LNP023 50 mg Bid/200 mg Bid	320.40	± 526.783

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus 7 days post treatment, up to a maximum duration of 115 weeks.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

LNP023 25mg Bid - Period 1

Serious: 0/7 (0%)

Deaths: 0/7

LNP023 50mg Bid - Period 1

Serious: 0/6 (0%)

Deaths: 0/6

LNP023 100mg Bid - Period 2

Serious: 0/7 (0%)

Deaths: 0/7

LNP023 200mg Bid - Period 2

Serious: 0/5 (0%)

Deaths: 0/5

LNP023 100mg Bid - Period 3

Serious: 0/7 (0%)

Deaths: 0/7

LNP023 200mg Bid - Period 3

Serious: 0/5 (0%)

Deaths: 0/5

Other adverse events (52 terms — click to expand)

Reaction	System	LNP023 25mg Bid - Period 1	LNP023 50mg Bid - Period 1	LNP023 100mg Bid - Period 2	LNP023 200mg Bid - Period 2	LNP023 100mg Bid - Period 3	LNP023 200mg Bid - Period 3
Headache	Nervous system disorders	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Breakthrough haemolysis	Blood and lymphatic system disorders	—	—	—	—	—	—
Eosinophilia	Blood and lymphatic system disorders	—	—	—	—	—	—
Haemolysis	Blood and lymphatic system disorders	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—
Autoimmune thyroiditis	Endocrine disorders	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—
Enterocolitis	Gastrointestinal disorders	—	—	—	—	—	—
Flatulence	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Upper limb fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Antinuclear antibody increased	Investigations	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—
Blood luteinising hormone increased	Investigations	—	—	—	—	—	—
Blood uric acid increased	Investigations	—	—	—	—	—	—
Blood urine present	Investigations	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—
Haematocrit increased	Investigations	—	—	—	—	—	—
Haemoglobin increased	Investigations	—	—	—	—	—	—
Reverse tri-iodothyronine increased	Investigations	—	—	—	—	—	—
Thyroxine free increased	Investigations	—	—	—	—	—	—
Gout	Metabolism and nutrition disorders	—	—	—	—	—	—
Impaired fasting glucose	Metabolism and nutrition disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT03896152 adverse events section.

Sponsor's own description

This was a Phase II randomized, open-label, multicenter, efficacy, safety, pharmacokinetic and pharmacodynamic study assessing four iptacopan doses in adult Paroxysmal nocturnal hemoglobinuria (PNH) patients with active hemolysis who were not on eculizumab or any other complement inhibitor less than 3 months prior to first iptacopan dose. Active hemolysis was defined by a lactate dehydrogenase (LDH) value ≥ 1.5 × ULN.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
Jang JH, Wong L, Ko BS, Yoon SS, et al · · 2022 · cited 64× · PMID 35561315 · DOI 10.1182/bloodadvances.2022006960
How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.
Risitano AM, Peffault de Latour R. · · 2022 · cited 48× · PMID 34355382 · DOI 10.1111/bjh.17753
Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A, Flohr S, Junt T, Eder J. · · 2023 · cited 27× · PMID 36217774 · DOI 10.1111/imr.13143
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies.
Yung S, Yap DY, Chan TM. · · 2020 · cited 22× · PMID 32789005 · DOI 10.12688/f1000research.22438.1
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
Bodó I, Amine I, Boban A, Bumbea H, et al · · 2023 · cited 15× · PMID 37072660 · DOI 10.1007/s12325-023-02510-4
Targeting of G-protein coupled receptors in sepsis.
Rehman A, Baloch NU, Morrow JP, Pacher P, et al · · 2020 · cited 11× · PMID 32197794 · DOI 10.1016/j.pharmthera.2020.107529
Factor B as a therapeutic target for the treatment of complement-mediated diseases.
Kavanagh D, Barratt J, Schubart A, Webb NJA, et al · · 2025 · cited 10× · PMID 40028332 · DOI 10.3389/fimmu.2025.1537974

Verify or expand the search:

Other trials of LNP023

Trials testing the same drug.

NCT06934967 — Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients · Phase 3 · recruiting
NCT06931691 — A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China · recruiting
NCT04557462 — A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P · Phase 3 · recruiting
NCT04578834 — Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients · Phase 3 · completed
NCT04558918 — Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antib · Phase 3 · completed

Other recruiting trials for Paroxysmal Nocturnal Hemoglobinuria

Currently open trials in the same condition.

NCT07457151 — Danicopan PMS in Korea · recruiting
NCT07154745 — A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hem · Phase 3 · recruiting
NCT07470762 — Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria · Phase 1, PHASE2 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07413679 — Long-term Safety of Danicopan: IPIG Registry-based Cohort Study · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03896152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 18 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03896152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03896152

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of LNP023

Other recruiting trials for Paroxysmal Nocturnal Hemoglobinuria

Other Novartis Pharmaceuticals trials

Verify against primary sources